Drug Profile
RND 001
Alternative Names: RND-001Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator RaNeDis Pharmaceuticals
- Developer AMO Pharma; RaNeDis Pharmaceuticals
- Class
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lysosomal storage diseases; Neurodegenerative disorders
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Lysosomal storage diseases in USA
- 28 Apr 2021 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA
- 14 Mar 2017 Preclinical trials in Lysosomal storage diseases and Neurodegenerative disorders in USA